ME2

Across TCGA pan-cancer cohorts, ME2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ME2 data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ME2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ME2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, HNSC, and UCEC are the cancer types where ME2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.272	0.688	<.001	33	view →
HNSC	DFS	Median	III,IV	0.162	0.594	.032	18	view →
UCEC	DFS	Median	All	1.000	0.828	.013	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ME2–LUAD (OS)

Open the LUAD breakdown →